Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Merus N.V. (NASDAQ: MRUS)*

Organization & Developments: Merus

Parents

2018: Merus: This ROTY Holding Flashed A Buy Signal - Merus (NASDAQ:MRUS)
2019: Kicking The Tires On Merus_seekingalpha.com
2019: Merus: Catalyst Filled 2020 For Biclonics Platform, Concerns Remain_seekingalpha.com
2022: Merus NV (MRUS) Investor Presentation- Slideshow_seekingalpha.com
2023: ESMO: Responses to Merus' NRG1+ drug edge up as biotech plans 'high-quality dossier' for FDA next year_ fiercebiotech
2023: Merus: (Maybe) Building A Better Bispecific_ seekingalpha.com
2024: FDA delays decision on Merus' first-in-class cancer drug by 3 months
2024: FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma
2024: FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri after brief delay
2024: Gilead bets on ‘trispecifics’ in latest cancer drug deal
2024: Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
2024: Merus receives FDA accelerated approval to treat NRG1+ cancers
2024: Merus Stock: Rally Seems Overdone_ seekingalpha.com
2024: Merus: Great European Oncology Developer, But Properly Valued
2024: Merus: Petosemtamab Set Up For December 2024 Data Presentation_
2024: Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
2024: US FDA extends review of Merus' gene-targeting cancer therapy
2025: Merus gains after mid-stage trial data for lead asset in head and neck cancer
2025: Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff_ seekingalpha.com